| Returns | 1W : -2% , 1M : -3.5%,1Y : 153.8% |
| Peers & Returns | 1W | 1M | 1Y |
| BAJAJ HEALTHCARE LTD | -2% | -3.5% | 153.8% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11.2% | 12.8% | 23.5% |
| DR REDDYS LABORATORIES LTD | 1.6% | -0.6% | 71.1% |
| DIVIS LABORATORIES LTD | 2.9% | 16.2% | 104.5% |
| CIPLA LTD | 3% | -1.9% | 62.2% |
| BIOCON LTD | 3.1% | 7.9% | 51.1% |
| AUROBINDO PHARMA LTD | 3.7% | 15.2% | 98.5% |
| LUPIN LTD | 4.6% | -1.2% | 15.5% |
| TORRENT PHARMACEUTICALS LTD | 2.1% | 2.5% | 42.4% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
27.79
P/E Calculated based on EPS of 16.31
[ Mar2020 - Standalone Results ] 5.58
P/B Calculated based on Book Value of 81.18
[ Mar2020 - Standalone Results ] 1.37
P/S Calculated based on Revenues of 458.148 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
NA 65% 74% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.81 0.91 1.19 0.97 |
- - - - |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Standalone | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
47.77% 31.07% 38.27% 31.55% |
105.51% 279.6% 522.79% 521.25% |
| QtrlyTrend |
8
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
